RE: https://mastodon.social/@cauZation/116567935744717669
Oooooh... Tagging for #SolarPunkSunday !
RE: https://mastodon.social/@cauZation/116567935744717669
Oooooh... Tagging for #SolarPunkSunday !
+++ Wie wirkt 🌱 😀 👯 #Cannabis auf das menschliche #Immunsystem❓ +++
🌱 #Cannabis ist in der Lage, das menschliche Immunsystem zu beeinflussen, so die #Studienergebnisse neuer #Forschungen. #THC und #CBD, die beiden wichtigsten Substanzen in der 🌱 #CannabisPflanze, interagierten mit dem körpereigenen #Endocannabinoidsystem. Sie können viele #Krankheiten & #Symptome #positivbeeinflussen. 🌱 #Hanf als #Heilpflanze steht mittlerweile im Fokus der #Wissenschaft. 🔭 #Hanfwissen
https://www.wissen.de/wie-wirkt-cannabis-auf-das-menschliche-immunsystem
Cannabis ist in der Lage, das menschliche Immunsystem zu beeinflussen, so die Studienergebnisse neuer Forschungen. THC und CBD, die beiden wichtigsten Substanzen in der Cannabis-Pflanze, interagierten mit dem körpereigenen Endocannabinoidsystem. Sie können viele Krankheiten und Symptome positiv beeinflussen. Hanf als Heilpflanze steht mittlerweile im Fokus der Wissenschaft. Dabei stellt sich die Frage, wie genau die positiven Effekte auf die menschliche Gesundheit aussehen. Am Ende kann Cannabis vielleicht sogar Autoimmunerkrankungen wie beispielsweise HIV heilen?
Study in mice suggests CBD may reduce brain inflammation linked to Alzheimer’s disease
📰 Original title: CBD may slow Alzheimer’s by calming the brain’s immune system
🤖 IA: It's not clickbait ✅
👥 Users: It's not clickbait ✅

A new study published in eNeuro suggests that cannabidiol (CBD), a compound derived from cannabis, may have the potential to reduce neuroinflammation associated with Alzheimer’s disease. Researchers from Augusta University investigated the effects of inhaled CBD in a well-established mouse model of Alzheimer’s. Their goal was to determine whether CBD could influence the chronic immune activation in the brain that is increasingly recognized as a major contributor to neurodegeneration. The findings indicate that CBD treatment reduced the activity of several key regulators involved in inflammatory signaling within the central nervous system. In addition, the treated mice showed lower levels of proinflammatory molecules, which are known to contribute to tissue damage and worsening cognitive decline. The researchers also identified specific immune-related pathways that appear to interact with CBD, suggesting that the compound may influence multiple biological mechanisms involved in the disease. Traditionally, Alzheimer’s research has focused on amyloid plaques and tau tangles as the primary drivers of brain damage. However, this study supports a growing body of evidence that chronic inflammation—sometimes described as an overactive immune response in the brain—also plays a central role in disease progression. According to the researchers, CBD may help address both protein buildup and immune dysfunction, pointing toward a possible multi-target therapeutic approach. Despite these promising results, the study was conducted in mice, not humans. This means that the findings cannot yet be directly applied to clinical treatment. Further research, including human clinical trials, will be necessary to determine whether CBD is safe and effective for people with Alzheimer’s disease. Nevertheless, the study adds to increasing scientific interest in targeting neuroinflammation as a strategy for slowing or modifying the course of neurodegenerative disorders.
Study in mice suggests CBD may reduce brain inflammation linked to Alzheimer’s disease
📰 Original title: CBD may slow Alzheimer’s by calming the brain’s immune system
🤖 IA: It's not clickbait ✅
👥 Users: It's not clickbait ✅

A new study published in eNeuro suggests that cannabidiol (CBD), a compound derived from cannabis, may have the potential to reduce neuroinflammation associated with Alzheimer’s disease. Researchers from Augusta University investigated the effects of inhaled CBD in a well-established mouse model of Alzheimer’s. Their goal was to determine whether CBD could influence the chronic immune activation in the brain that is increasingly recognized as a major contributor to neurodegeneration. The findings indicate that CBD treatment reduced the activity of several key regulators involved in inflammatory signaling within the central nervous system. In addition, the treated mice showed lower levels of proinflammatory molecules, which are known to contribute to tissue damage and worsening cognitive decline. The researchers also identified specific immune-related pathways that appear to interact with CBD, suggesting that the compound may influence multiple biological mechanisms involved in the disease. Traditionally, Alzheimer’s research has focused on amyloid plaques and tau tangles as the primary drivers of brain damage. However, this study supports a growing body of evidence that chronic inflammation—sometimes described as an overactive immune response in the brain—also plays a central role in disease progression. According to the researchers, CBD may help address both protein buildup and immune dysfunction, pointing toward a possible multi-target therapeutic approach. Despite these promising results, the study was conducted in mice, not humans. This means that the findings cannot yet be directly applied to clinical treatment. Further research, including human clinical trials, will be necessary to determine whether CBD is safe and effective for people with Alzheimer’s disease. Nevertheless, the study adds to increasing scientific interest in targeting neuroinflammation as a strategy for slowing or modifying the course of neurodegenerative disorders.
Como será o futuro do varejo da cannabis no Brasil?
#Cannabis médical , une question de santé publique, à quand la légalisation ?!
Alors que des centaines de milliers de personnes y voient un espoir pour soulager leurs douleurs chroniques, l’autorisation du cannabis médical est soumise depuis huit ans en France à un infernal « stop-and-go ».
92% des Français ne font pas l’amalgame avec le cannabis « récréatif », à rebours de certains responsables politiques. La filière CBD Bien-être, elle, est toujours dans le collimateur. #cbd #antifas
Ahir llegia que el lli (Linum usitatissimum) conté substàncies anàlogues al CBD del cànnabis que, com aquest, activen el receptor cannabinoide perifèric 2 (CB2). Aquest receptor es troba principalment en el sistema immunitari i és el responsable de modular la inflamació sense afectar el sistema nerviós central.
Aquest efecte se suma al seu alt contingut en Omega-3 (àcid alfa-linolènic) i lignans, que també ajuden a reduir la inflamació.
I que s'estan estudiant venes o gases fetes de fibres de lli per a la cura de ferides cròniques (com úlceres), aprofitant la seva capacitat per reduir la inflamació directament sobre la pell.
I pensava en les teles de lli, en dormir amb llençols fets de les seves fibres, que també contenen aquesta substància. Llençols relaxants. 😍
Bé doncs, avui, regant, m'he adonat que m'està creixent lli en un test. Alguna llavor perduda. Visca les llavors perdudes que ens porten agradables sorpreses matineres!
#cbd #cannabinoide #omega3 #inflamacio #inflamacion #cannabis #cannabidiol #fitoterapia
Premium CBD från Gotland, Kvalitet & ursprung
Skillnaden mellan industri-CBD och premium-CBD är större än många tror, råvara, jord, växtprofil och spårbarhet. Varför Helsama valt en annan väg.
What’s Your Vibe Today?
Kick back with custom edibles & gummies made for smooth, mellow vibes From D9/CBD Blood Orange Canna Bliss to Delta-8 Gummies, tinctures & more . Find your perfect chill.
Ready to vibe? Shop now at https://www.snapdragonhemp.com/
El Tribunal Supremo endurece el criterio penal sobre flores de cáñamo y productos CBD en España
📰 Título original: Sentencia Tribunal Supremo sobre flores de cáñamo y CBD que lo cambia todo en España
🤖 IA: Es clickbait ⚠️
👥 Usuarios: Es clickbait ⚠️
Ver resumen IA completo: https://es.killbait.com/el-tribunal-supremo-endurece-el-criterio-penal-sobre-flores-de-canamo-y-productos-cbd-en-espana.html?utm_source=masto_es&utm_medium=social&utm_campaign=killbait.masto_es

Una reciente sentencia del Tribunal Supremo español, la STS 1993/2026, ha generado una fuerte preocupación en el sector del cáñamo industrial y del CBD al considerar que determinadas flores y productos derivados del cáñamo pueden ser tratados como estupefacientes aunque tengan bajos niveles de THC. La resolución establece que productos comercializados en formatos de consumo individual, como cogollos o cigarrillos de cáñamo, podrían entrar dentro del ámbito penal si la cantidad total de THC supera los 10 miligramos, incluso cuando proceden de variedades autorizadas por la Unión Europea y respetan el límite legal del 0,3% de THC. El artículo sostiene que esta interpretación rompe con anteriores criterios del propio Tribunal Supremo, que exigían demostrar capacidad psicoactiva real para considerar una sustancia como droga tóxica. Además, denuncia que la nueva doctrina contradice la jurisprudencia del Tribunal de Justicia de la Unión Europea, especialmente las sentencias Kanavape y Biohemp Concept, que consideran que el CBD no es un estupefaciente y que cualquier restricción debe basarse en evidencias científicas y respetar la proporcionalidad. Los despachos Lawyer Sierra y Brotsanbert anuncian acciones legales para intentar revertir la sentencia mediante recursos ante el Tribunal Supremo, el Tribunal Constitucional y, eventualmente, el Tribunal Europeo de Derechos Humanos. También recomiendan a empresas y operadores del sector revisar urgentemente formatos de venta, etiquetado y documentación comercial para reducir riesgos legales mientras se resuelve el conflicto jurídico entre la interpretación española y el marco europeo.